started · updated
Novo Nordisk faces lawsuits over Ozempic and NAION risks
Lawsuits are mounting against Novo Nordisk, alleging that GLP-1 drugs like Ozempic can cause serious, life-altering side effects, including non-arteritic anterior ischemic optic neuropathy (NAION).
One such case involves Todd Engel, who developed NAION—an inoperable condition caused by blood flow restriction to the eye—after being prescribed Ozempic for diabetes. Engel's lawsuit claims the manufacturer failed to adequately warn patients and medical professionals about this risk. His case is part of larger consolidated litigation regarding the safety of GLP-1 medications.
Research published in JAMA Ophthalmology has indicated higher rates of NAION among diabetic patients using semaglutide, the active ingredient in Ozempic. However, Novo Nordisk has dismissed the claims as meritless, pointing to subsequent research that casts doubt on a causal link between the drug and the condition. The widespread use of these drugs is significant, with Gallup reporting that over one in 10 Americans use GLP-1s for weight loss.
Entities
Gallup · JAMA Ophthalmology · Novo Nordisk · Ozempic · Todd Engel
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 3 SOURCES] Research published in JAMA Ophthalmology indicates higher rates of NAION among diabetic patients using Ozempic. www.europesays.com · www.ksfr.org · www.kpbs.org
- [● 3 SOURCES] Todd Engel filed a lawsuit against Novo Nordisk, alleging the company failed to warn about the risk of NAION. www.europesays.com · www.ksfr.org · www.kpbs.org
- [● 3 SOURCES] Novo Nordisk spokespeople stated the legal cases are without merit and cited research casting doubt on the link between their drug and NAION. www.europesays.com · www.ksfr.org · www.kpbs.org
- [● 3 SOURCES] According to Gallup analysis, more than one in 10 Americans use GLP-1 drugs for weight loss. www.europesays.com · www.ksfr.org · www.kpbs.org